home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Partners In Crime

  March, 15 2006 10:08
your information resource in human molecular genetics
Scientists have defined the detailed architecture of an enzyme crucial for the replication of two major human viruses. The results, reported in the April issue of Nature Structural & Molecular Biology, will guide the discovery of new antiviral drugs.

Hommel and colleagues study a viral enzyme called NS3pro from Dengue and West Nile viruses. NS3pro processes newly synthesized viral proteins, an event that is required for the replication of both viruses. The activity of NS3pro depends on another viral protein called NS2B. NS2B activates NS3pro, but how it does this was not known. The authors have determined three-dimensional structures of West Nile and Dengue viruses NS3pro bound to NS2B. These structures reveal that NS2B activates NS3pro by helping it to recognize its targets.

An estimated 2.5 billion people are at risk of infection from Dengue and West Nile viruses. At present, no vaccine or treatment is available to prevent or cure these diseases, so this information will aid the development of new drugs against West Nile and Dengue viruses.

Author contact:

Ulrich Hommel (Novartis Institutes for Biomedical Research, Basel, Switzerland)
E-mail: ulrich.hommel@novartis.com

Abstract available online.

(C) Nature Structural & Molecular Biology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.